Related Experiment Videos
p53 independent G(1) arrest induced by DL-alpha-difluoromethylornithine
1Department of Physiological Chemistry and Metabolism, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
Abstract:
Ornithine decarboxylase (ODC), which catalyzes polyamine biosynthesis, plays an essential role in cell growth. DL-alpha-Difluoromethylornithine (DFMO), a synthetic inhibitor of ODC, inhibits cell growth. However, the exact mechanism by which polyamine depletion by DFMO results in growth inhibition remains to be elucidated. We clarified the mechanisms by which DFMO inhibits human gastric cancer cell (MKN45) growth. DFMO induced MKN45 cell G(1) phase arrest after 48 h, and the percentage of G(1) arrest cells continued to increase until 72 h. Expression of p21 and phosphorylation of Stat1 were significantly induced by DFMO at 24 h. Luciferase assay and gel shift assay showed specific binding of Stat1 to the p21 promoter, and promoter activity was activated at 24 h. In dominant negative p53 expressing cells, DFMO significantly induced p21 expression, arrested cells at G(1) phase, and suppressed cell growth effectively. These results suggest that DFMO induced MKN45 cell arrest at G(1) phase in a p53 independent manner, and Stat1 is, at least in part, involved in G(1) arrest.
Insights
DL-alpha-Difluoromethylornithine (DFMO) inhibits human gastric cancer cell growth by causing G(1) phase arrest. This process involves p21 induction and Stat1 activation, independent of p53, highlighting a novel cancer treatment pathway.
Area of Science:
- Cell Biology
- Molecular Biology
- Oncology
Background:
- Ornithine decarboxylase (ODC) regulates polyamine biosynthesis, crucial for cell proliferation.
- DL-alpha-Difluoromethylornithine (DFMO) is a known ODC inhibitor that reduces cell growth.
- The precise mechanism of DFMO-induced growth inhibition via polyamine depletion requires further elucidation.
Purpose of the Study:
- To investigate the molecular mechanisms by which DFMO inhibits human gastric cancer cell (MKN45) growth.
- To determine the role of cell cycle regulation and specific signaling pathways in DFMO's anti-proliferative effects.
Main Methods:
- Cell culture of human gastric cancer cell line (MKN45).
- Flow cytometry to analyze cell cycle phase distribution (G(1) arrest).
- Western blotting to assess protein expression (p21, phosphorylated Stat1).
- Luciferase and gel shift assays to evaluate Stat1 binding to the p21 promoter.
Main Results:
- DFMO treatment led to significant G(1) phase arrest in MKN45 cells, increasing over time.
- DFMO induced the expression of p21 and phosphorylation of Stat1.
- Stat1 was shown to bind specifically to the p21 promoter, activating its activity.
- DFMO effectively inhibited cell growth and induced G(1) arrest even in cells with dominant-negative p53 expression.
Conclusions:
- DFMO induces G(1) phase arrest in human gastric cancer cells through a p53-independent pathway.
- Stat1 activation and subsequent p21 induction play a significant role in mediating DFMO's G(1) arrest effect.
- These findings provide insights into the anti-cancer mechanisms of DFMO and suggest its potential therapeutic utility.